Maverix Biomics and Elsevier Sign NGS Data Interpretation Agreement
By Bio-IT World Staff
February 16, 2015 | Maverix Biomics signed a strategic agreement with Elsevier this morning at CHI’s Molecular Medicine Tri-Conference in San Francisco. The Maverix Analytic Platform will complement Elsevier’s Pathway Studio sample-to-insight workflow and incorporate biological data from Elsevier’s biology journals by providing easy, push-button data analysis. Financial terms of the agreement were not disclosed.
The integrated solution will start with raw NGS data and produce genome alignment, quality metrics, variant and expression analysis, and the ability to analyze and visualize disease mechanisms derived from published scientific data.
“This collaboration gives more value to our customers—not only can they use the two great tools our companies produce, but they can now save time by seamlessly using them together. This reduces their workload, reduces complexity and increases accuracy of their analysis,” said Jaqui Hodgkinson, VP Product Development of Elsevier Life Sciences Solutions, in the announcement.